{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:05:12Z","timestamp":1791389112288,"version":"4.3.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MDACC CORE grant start up funds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Molecular glioblastoma (molGBM) is a variant lacking the full histopathological profile of glioblastoma. We report a trial aimed at addressing the optimal management of this newly recognized rarer form of glioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase II study, molGBM patients were treated with radiation to a dose of 60Gy to the gross tumor volume (GTV) only, and a single smaller margin potentially as low as 1cm to the clinical tumor volume (CTV). As the trial is ongoing, we report on important exploratory biomarker findings correlating with median overall survival (mOS). Analysis included Kaplan-Meier and univariable\/multivariable cox proportional hazard models. Available pre-operative tissue was subjected to epigenetic\/DNA methylation profiling on the Infinium EPIC platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2019 to 2023, 25 patients were enrolled based on initial pathology review, with 23 identified on 2nd review as grade 2 and 3 disease. 74% of patients received concurrent chemoradiotherapy with adjuvant chemotherapy. Of 9 patients with profiling, 5 were classified as mesenchymal subtype, while 4 matched to a variety of other phenotypes, including a novel F type GBM. Despite similar histological appearance corresponding to \u201clower grade glioma\u201d, molGBM classified as IDH-wildtype mesenchymal had mOS of 15.7 months (95% CI 15.5-NA) while the other tumors had a mOS of 37.7 months (95% CI 10.9-NA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results demonstrate underlying heterogeneity within the molGBM population, pointing to future hypothesis-generating risk stratification strategies. We also demonstrate the feasibility of CTV reduction with therapy intensification to set a practice standard for RT management of non-enhancing molGBM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-025-05269-6","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:22:43Z","timestamp":1762330963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses"],"prefix":"10.1007","volume":"176","author":[{"given":"Debra Nana","family":"Yeboa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin T.","family":"Whitfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinenye Lynette","family":"Ejezie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Beckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subha","family":"Perni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Tom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin K.","family":"Majd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Puduvalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Aaroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Loghin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Wefel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceylan Altintas","family":"Taslicay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gule-Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold C.","family":"Paulino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"McAleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Grosshans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol J.","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Maor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Gubbiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Kamiya-Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leomar Y.","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiao-Pei","family":"Weathers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Huse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"5269_CR1","doi-asserted-by":"publisher","unstructured":"Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR,Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H,Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M,Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O\u2019Neill BP,Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T,Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ,Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S,Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG,Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A,Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD,Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T,Jr., Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T,Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D,Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB,Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G,Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG, Jr., Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F,Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M,McLendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372:2481\u20132498 https:\/\/doi.org\/10.1056\/NEJMoa1402121","DOI":"10.1056\/NEJMoa1402121"},{"key":"5269_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-022-03960-6","volume":"157","author":"A Ramos-Fresnedo","year":"2022","unstructured":"Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP, Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR, Trifiletti DM, Chaichana KL, Porter AB, Quinones-Hinojosa A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ (2022) The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol 157:177\u2013185. https:\/\/doi.org\/10.1007\/s11060-022-03960-6","journal-title":"J Neurooncol"},{"key":"5269_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2021.12.009","volume":"167","author":"X Qiu","year":"2022","unstructured":"Qiu X, Chen Y, Bao Z, Chen L, Jiang T (2022) Chemoradiotherapy with Temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II\/III gliomas: A prospective randomized study. Radiother Oncol 167:1\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2021.12.009","journal-title":"Radiother Oncol"},{"key":"5269_CR4","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O\u2019Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499\u20132508. https:\/\/doi.org\/10.1056\/NEJMoa1407279","journal-title":"N Engl J Med"},{"key":"5269_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ng.3273","volume":"47","author":"H Suzuki","year":"2015","unstructured":"Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458\u2013468. https:\/\/doi.org\/10.1038\/ng.3273","journal-title":"Nat Genet"},{"key":"5269_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00401-015-1409-0","volume":"129","author":"M Weller","year":"2015","unstructured":"Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Loffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Bostrom J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G (2015) Molecular classification of diffuse cerebral WHO grade II\/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679\u2013693. https:\/\/doi.org\/10.1007\/s00401-015-1409-0","journal-title":"Acta Neuropathol"},{"key":"5269_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"5269_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/neuonc\/noad158","volume":"26","author":"H Pinson","year":"2024","unstructured":"Pinson H, Silversmit G, Vanhauwaert D, Vanschoenbeek K, Okito JK, De Vleeschouwer S, Boterberg T, De Gendt C (2024) Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era. Neurooncology 26:191\u2013202. https:\/\/doi.org\/10.1093\/neuonc\/noad158","journal-title":"Neurooncology"},{"key":"5269_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK (2013) Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 13:152. https:\/\/doi.org\/10.1186\/1471-2288-13-152","journal-title":"BMC Med Res Methodol"},{"key":"5269_CR10","doi-asserted-by":"publisher","unstructured":"Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, H\u00f6lsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Br\u00fcck W, Hofer S, Brehmer S, Seiz-Rosenhagen M, H\u00e4nggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, M\u00fchleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, M\u00fcller HL, Rutkowski S, von Hoff K, Fr\u00fchwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Bl\u00fcmcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Sch\u00fcller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469\u2013474 https:\/\/doi.org\/10.1038\/nature26000","DOI":"10.1038\/nature26000"},{"key":"5269_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ijrobp.2014.11.012","volume":"91","author":"BJ Fisher","year":"2015","unstructured":"Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, Ryu S, Werner-Wasik M, Bahary JP, Liu J, Chakravarti A, Mehta M (2015) Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of radiation therapy oncology group 0424. Int J Radiat Oncol Biol Phys 91:497\u2013504. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.11.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5269_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2021.12.009","volume":"167","author":"X Qiu","year":"2022","unstructured":"Qiu X, Chen Y, Bao Z, Chen L, Jiang T (2022) Chemoradiotherapy with Temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II\/III gliomas: A prospective randomized study. Radiotherapy Oncol 167:1\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2021.12.009","journal-title":"Radiotherapy Oncol"},{"key":"5269_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","volume":"22","author":"MJ van den Bent","year":"2021","unstructured":"van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG (2021) Adjuvant and concurrent Temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053\u2009\u2013\u200922054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22:813\u2013823. https:\/\/doi.org\/10.1016\/S1470-2045(21)00090-5","journal-title":"Lancet Oncol"},{"key":"5269_CR14","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/1078-0432.CCR-21-4283","volume":"28","author":"CMS Tesileanu","year":"2022","unstructured":"Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rud\u00e0 R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ (2022) Temozolomide and radiotherapy versus radiotherapy alone in patients with Glioblastoma, IDH-wildtype: post hoc analysis of the EORTC randomized phase III CATNON trial. Clin Cancer Res 28:2527\u20132535. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4283","journal-title":"Clin Cancer Res"},{"key":"5269_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11060-021-03891-8","volume":"156","author":"CR Garcia","year":"2022","unstructured":"Garcia CR, Myint ZW, Jayswal R, Wang C, Morgan RM, Butts AR, Weiss HL, Villano JL (2022) Hematological adverse events in the management of glioblastoma. J Neurooncol 156:153\u2013161. https:\/\/doi.org\/10.1007\/s11060-021-03891-8","journal-title":"J Neurooncol"},{"key":"5269_CR16","doi-asserted-by":"publisher","first-page":"101717","DOI":"10.1016\/j.adro.2025.101717","volume":"10","author":"JK Matsui","year":"2025","unstructured":"Matsui JK, Swanson D, Allen P, Perlow HK, Bradshaw J, Beckham TH, Tom MC, Wang C, Perni S, Yeboa DN, Ghia AJ, McAleer MF, Li J, Palmer JD, McGovern SL (2025) Reduced treatment volumes for glioblastoma associated with lower rates of radionecrosis and lymphopenia: A pooled analysis. Adv Radiat Oncol 10:101717. https:\/\/doi.org\/10.1016\/j.adro.2025.101717","journal-title":"Adv Radiat Oncol"},{"key":"5269_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/nan.12669","volume":"47","author":"Y Braun","year":"2021","unstructured":"Braun Y, Filipski K, Bernatz S, Baumgarten P, Roller B, Zinke J, Zeiner PS, Ilina E, Senft C, Ronellenfitsch MW, Plate KH, Bahr O, Hattingen E, Steinbach JP, Mittelbronn M, Harter PN (2021) Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma. Neuropathol Appl Neurobiol 47:379\u2013393. https:\/\/doi.org\/10.1111\/nan.12669","journal-title":"Neuropathol Appl Neurobiol"},{"key":"5269_CR18","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41588-021-00927-7","volume":"53","author":"R Chaligne","year":"2021","unstructured":"Chaligne R, Gaiti F, Silverbush D, Schiffman JS, Weisman HR, Kluegel L, Gritsch S, Deochand SD, Gonzalez Castro LN, Richman AR, Klughammer J, Biancalani T, Muus C, Sheridan C, Alonso A, Izzo F, Park J, Rozenblatt-Rosen O, Regev A, Suva ML, Landau DA (2021) Epigenetic encoding, heritability and plasticity of glioma transcriptional cell States. Nat Genet 53:1469\u20131479. https:\/\/doi.org\/10.1038\/s41588-021-00927-7","journal-title":"Nat Genet"},{"key":"5269_CR19","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/s41591-024-02969-w","volume":"30","author":"R Drexler","year":"2024","unstructured":"Drexler R, Khatri R, Sauvigny T, Mohme M, Maire CL, Ryba A, Zghaibeh Y, Duhrsen L, Salviano-Silva A, Lamszus K, Westphal M, Gempt J, Wefers AK, Neumann JE, Bode H, Hausmann F, Huber TB, Bonn S, Jutten K, Delev D, Weber KJ, Harter PN, Onken J, Vajkoczy P, Capper D, Wiestler B, Weller M, Snijder B, Buck A, Weiss T, Goller PC, Sahm F, Menstel JA, Zimmer DN, Keough MB, Ni L, Monje M, Silverbush D, Hovestadt V, Suva ML, Krishna S, Hervey-Jumper SL, Schuller U, Heiland DH, Hanzelmann S, Ricklefs FL (2024) A prognostic neural epigenetic signature in high-grade glioma. Nat Med 30:1622\u20131635. https:\/\/doi.org\/10.1038\/s41591-024-02969-w","journal-title":"Nat Med"},{"key":"5269_CR20","doi-asserted-by":"publisher","first-page":"15668","DOI":"10.1038\/s41598-021-95009-3","volume":"11","author":"IE Grabowicz","year":"2021","unstructured":"Grabowicz IE, Wilczynski B, Kaminska B, Roura AJ, Wojtas B, Dabrowski MJ (2021) The role of epigenetic modifications, long-range contacts, enhancers and topologically associating domains in the regulation of glioma grade-specific genes. Sci Rep 11:15668. https:\/\/doi.org\/10.1038\/s41598-021-95009-3","journal-title":"Sci Rep"},{"key":"5269_CR21","doi-asserted-by":"publisher","first-page":"1089898","DOI":"10.3389\/fcell.2022.1089898","volume":"10","author":"A Groves","year":"2022","unstructured":"Groves A, Cooney TM (2022) Epigenetic programming of pediatric high-grade glioma: pushing beyond proof of concept to clinical benefit. Front Cell Dev Biol 10:1089898. https:\/\/doi.org\/10.3389\/fcell.2022.1089898","journal-title":"Front Cell Dev Biol"},{"key":"5269_CR22","doi-asserted-by":"publisher","unstructured":"Jones C, Baker SJ (2014) Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer 14. https:\/\/doi.org\/10.1038\/nrc3811","DOI":"10.1038\/nrc3811"},{"key":"5269_CR23","doi-asserted-by":"publisher","first-page":"831636","DOI":"10.3389\/fimmu.2022.831636","volume":"13","author":"K Kanwore","year":"2022","unstructured":"Kanwore K, Kanwore K, Adzika GK, Abiola AA, Guo X, Kambey PA, Xia Y, Gao D (2022) Cancer metabolism: the role of immune cells epigenetic alteration in Tumorigenesis, Progression, and metastasis of glioma. Front Immunol 13:831636. https:\/\/doi.org\/10.3389\/fimmu.2022.831636","journal-title":"Front Immunol"},{"key":"5269_CR24","doi-asserted-by":"publisher","unstructured":"Liao CH, Lai IC, Kuo HC, Chuang SE, Lee HL, Whang-Peng J, Yao CJ, Lai GM (2019) Epigenetic modification and differentiation induction of malignant glioma cells by oligo-fucoidan. Mar Drugs 17. https:\/\/doi.org\/10.3390\/md17090525","DOI":"10.3390\/md17090525"},{"key":"5269_CR25","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/neuonc\/noy003","volume":"20","author":"P Liao","year":"2018","unstructured":"Liao P, Ostrom QT, Stetson L, Barnholtz-Sloan JS (2018) Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence. Neuro Oncol 20:942\u2013953. https:\/\/doi.org\/10.1093\/neuonc\/noy003","journal-title":"Neuro Oncol"},{"key":"5269_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/neuonc\/noad197","volume":"26","author":"A Eckhardt","year":"2024","unstructured":"Eckhardt A, Drexler R, Schoof M, Struve N, Capper D, Jelgersma C, Onken J, Harter PN, Weber KJ, Div\u00e9 I, Rothkamm K, Hoffer K, Klumpp L, Ganser K, Petersen C, Ricklefs F, Kriegs M, Sch\u00fcller U (2024) Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastoma. Neuro Oncol 26:503\u2013513. https:\/\/doi.org\/10.1093\/neuonc\/noad197","journal-title":"Neuro Oncol"},{"key":"5269_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O\u2019Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research N (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98\u2013110. https:\/\/doi.org\/10.1016\/j.ccr.2009.12.020","journal-title":"Cancer Cell"},{"key":"5269_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13148-021-01085-7","volume":"13","author":"S Ferreyra Vega","year":"2021","unstructured":"Ferreyra Vega S, Olsson Bontell T, Corell A, Smits A, Jakola AS, Car\u00e9n H (2021) DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. Clin Epigenetics 13:102. https:\/\/doi.org\/10.1186\/s13148-021-01085-7","journal-title":"Clin Epigenetics"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05269-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:34:46Z","timestamp":1767702886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05269-6"}},"subtitle":["Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy"],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5269"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05269-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Harrison discloses: Consulting- Servier Canada, Novocure; Honorarium: Pfizer, EMD Serono. Dr. CB Patel discloses: McNair Scholar supported by the McNair Medical Institute at The Robert and Janice McNair Foundation. Dr. Weathers discloses: Genentech and Exelixis trial support for unrelated clinical trials. Dr. McGovern discloses: Chimerix Advisory Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures (all unrelated to current study)"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}